CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis ↧

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis ↧ ↧ CSL strikes rare disease drug deal worth up to $1.6 billion with Sw... Australia's CSL said on Monday it had entered into an agreement with ​Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for ‌rare kidney and liver diseases, in a deal worth up to $1.6 billion, excluding development funding.